HUBERT DOLUBIZNO: Open Payments
NPI 1578188462 · ALEXANDRIA, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$412 in 18 payments from 9 companies in 2025. Trend: 2023 $217 · 2024 $1,730 · 2025 $412
Food & beverage: $412
| Company | Payments | Amount |
|---|---|---|
| Axsome Therapeutics, Inc. | 1 | $115 |
| ABBVIE INC. | 6 | $102 |
| AstraZeneca Pharmaceuticals LP | 3 | $58 |
| Novo Nordisk Inc | 2 | $38 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $35 |
| PFIZER INC. | 1 | $19 |
| Exact Sciences Corporation | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $15 |
Products named: Auvelity, VRAYLAR, CAPLYTA, UBRELVY, QULIPTA, AIRSUPRA, Ozempic, Wegovy.
Industry payments across IN — which companies pay providers there.
